Press Release Dec 06 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received final approval from the USFDA for Methylene Blue Injection, which will be available in two formulations. This approval allows Zydus to manufacture and market a generic version of the drug, providing a more affordable vial presentation compared to the traditional ampoule. The injection is indicated for treating methemoglobinemia in both pediatric and adult patients, and the US market for this product had significant annual sales.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 01 2023
- Press Release Nov 10 2023
- Press Release Nov 07 2023
- Press Release Nov 06 2023
- Press Release Nov 03 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Dec 11 2023
- Press Release Dec 14 2023
- Press Release Dec 15 2023
- Press Release Dec 16 2023
- Press Release Dec 22 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences